Skip to main content
. 2020 Aug 6;5(15):e137062. doi: 10.1172/jci.insight.137062

Figure 3. Neutralization of FGF 23 delays the onset of anemia.

Figure 3

Eight-week-old NUP98/HOXD13 (NHD13) mice and their littermate WT (WT) mice were treated with FGF-23 neutralizing Ab over 8 weeks. (A and B) Throughout the experiment, retrobulbar blood of the mice was used to analyze blood parameters, hemoglobin levels (n = 17–19) and RBC (n = 17–19), once a month. Data are shown as means ± SD of 12 independent experiments. (C and D) Bone marrow cells were used to determine the total number of LSK by flow cytometry (n = 7–8) (C) and the number of erythroid colonies using burst-forming unit erythroid assay (n = 7–9) (D). Erythroid colonies were counted after 8 days of cultivation. Data are shown as mean ± SD of 5 independent experiments. Statistical analysis was performed by 2-way ANOVA for the effect of MDS, FGF‑23 Ab treatment, and the interaction of both. Statistical significance of Bonferroni’s multiple comparisons is denoted. *P < 0.05 vs. control. #P < 0.05; ##P < 0.01; ###P < 0.001 vs. WT control.